Immunovaccine Technologies (IVT), a vaccine development company, announced today that it has appointed Gary Dodge, CA, as Chief Financial Officer.
Reporting to president and CEO Dr. Randal Chase, Mr. Dodge will oversee IVT’s accounting and financing activities. Mr. Dodge also becomes a part of the company’s executive management team, which directs all aspects of company strategy, planning, and operations.
“We received a lot of interest in the CFO position and met with many impressive candidates,” said Dr. Chase. “However, with Gary’s experience in public company reporting, international accounting, and financial controls, we knew he would be the right fit.”
“After meeting with Randal and the team, I was thoroughly impressed with everyone’s drive and sense of purpose to develop breakthrough vaccines,” remarked Mr. Dodge. “I’m excited to join this effort and this vibrant company.”
Prior to joining IVT, Mr. Dodge was SolutionInc Technologies Ltd’s CFO and was responsible for financial reporting, capital financing, and financial planning. He was also a Director, Transaction Services, for PricewaterhouseCoopers LLP. While working in PwC’s Calgary, Johannesburg and Boston offices, Mr. Dodge performed audit and advisory services across many industries, including mergers and acquisitions advisory services to both biotech companies and private equity clients.
ImmunoVaccine Technologies is a vaccine development company focused on the commercialization of its novel vaccine candidates. IVT continues to strengthen its vaccine pipeline through licensing and strategic partnering to develop therapeutic cancer and infectious disease vaccines. WWW.IMMUNOVACCINE.COM.
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future are forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. IVT assumes no responsibility to update forward-looking statements in this press release.
For more information, please contact:
Jennifer Ayotte, Communications
T: (902) 209-4704
Halifax, Nova Scotia, September 28, 2009